Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 7/2021

01-07-2021 | Polymyositis | Original Article

The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease

Authors: Hung-Ling Huang, Wen-Chih Lin, Po-Yu Lin, Meng-Yu Weng, Yuan-Ting Sun

Published in: Neurological Sciences | Issue 7/2021

Login to get access

Abstract

Aim

This study identified factors associated with interstitial lung disease (ILD) in patients with idiopathic inflammatory myopathy (IIM) based on the latest classification and recent advances in autoantibody serology.

Methods

We retrospectively analyzed data of 173 patients who underwent complete myositis autoantibody serology examination in a medical center in Taiwan from July 2018 to February 2020. After exclusion of patients who did not receive a final diagnosis of IIM, clinical features, serology data, concomitant diseases, treatment, presence of respiratory failure, and mortality rate of the remaining 97 patients were analyzed.

Results

Of IIM patients in our cohort, 47.4% had ILD. ILD was significantly associated with subtypes of IIM, older age of onset, presence of mechanic’s hand, and presence of anti-Jo-1 and anti-Ro52 antibodies. Among five IIM subtypes, overlap myositis (OM) and dermatomyositis (DM) were significantly associated with a higher prevalence rate of ILD (67.5% in OM and 53.3% in DM). Among patients with OM, the presence of anti-Jo-1 (100%), anti-PL-7 (100%), and anti-EJ antibodies (77.8%) was most significantly associated with ILD.

Conclusion

The latest classification of IIM, older age of onset, presence of mechanic’s hand, and presence of anti-Jo-1 and anti-Ro52 antibodies were significantly associated with ILD. Among five IIM subtypes, OM and DM had higher prevalence rate of ILD. Among OM patients, the presence of anti-Jo-1, anti-EJ, and anti-PL-7 antibodies was significantly associated with ILD. The study results may help physicians to timely screen and monitor pulmonary function in high-risk groups.
Literature
1.
Mimori T, Nakashima R, Hosono Y (2012) Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 14(3):264–274PubMed
2.
Kiely PD, Chua F (2013) Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis. Curr Rheumatol Rep 15(9):359PubMed
3.
Schnabel A, Reuter M, Biederer J, Richter C, Gross WL (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32(5):273–284PubMed
4.
Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V (2015) Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 24(136):216–238PubMed
5.
Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, Christopher-Stine L, Danoff S (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194(5):733–737PubMed
6.
Barba T, Mainbourg S, Nasser M, Lega JC, Cottin V (2019) Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med 40(2):255–270PubMed
7.
Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17(9):816–828PubMed
8.
9.
Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14(5):269–278PubMed
10.
Leclair V, Lundberg IE (2018) New myositis classification criteria-what we have learned since Bohan and Peter. Curr Rheumatol Rep 20(4):18PubMedPubMedCentral
11.
Senecal JL, Raynauld JP, Troyanov Y (2017) Editorial: a new classification of adult autoimmune myositis. Arthritis Rheumatol 69(5):878–884PubMed
12.
Fredi M, Cavazzana I, Franceschini F (2018) The clinico-serological spectrum of overlap myositis. Curr Opin Rheumatol 30(6):637–643PubMed
13.
Benveniste O, Stenzel W, Allenbach Y (2016) Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 29(5):662–673PubMed
14.
Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52(1):1–19PubMedPubMedCentral
15.
McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290–302PubMed
16.
Li L, Wang H, Wang Q, Wu C, Liu C, Zhang Y, Cheng L, Zeng X, Zhang F, Li Y (2019) Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. J Neurol Sci 397:123–128PubMed
17.
Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T (2016) Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med 121:91–99PubMed
18.
19.
Chen F, Li S, Wang T, Shi J, Wang G (2018) Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies. Am J Med Sci 355(1):48–53PubMed
20.
Zhang L, Wu G, Gao D, Liu G, Pan L, Ni L, Li Z, Wang Q (2016) Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One 11(5):e0155381PubMedPubMedCentral
21.
Katzap E, Barilla-LaBarca ML, Marder G (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13(3):175–181PubMed
22.
Marco JL, Collins BF (2020) Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol 34:101503PubMed
23.
Cruellas MG, Viana VS, Levy-Neto M, Souza FH, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 68(7):909–914PubMedPubMedCentral
24.
Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, Levesque H, Jouen F (2012) Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41(6):890–899PubMed
25.
Rutjes SA et al (1997) Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 109(1):32–40PubMedPubMedCentral
26.
Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ (2010) Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 86(1012):79–82PubMed
27.
Huang HL, Lin WC, Yeh CC, Sun YT (2020) Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy. J Clin Neurosci 74:32–35PubMed
28.
Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL, Childhood Myositis Heterogeneity Collaborative Study Group (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78(7):988–995PubMed
29.
Ferreira JP et al (2012) Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol 2012:415272PubMedPubMedCentral
30.
Sasano H, Hagiwara E, Kitamura H, Enomoto Y, Matsuo N, Baba T, Iso S, Okudela K, Iwasawa T, Sato S, Suzuki Y, Takemura T, Ogura T (2016) Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy. BMC Pulm Med 16(1):168PubMedPubMedCentral
31.
Ota M et al (2016) Anti-EJ antibody positive interstitial lung disease with skin changes at the fingertips. Nihon Rinsho Meneki Gakkai Kaishi 39(2):150–153PubMed
32.
Trallero-Araguas E et al (2016) Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum 46(2):225–231PubMed
33.
Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, Silhan L, Christopher-Stine L, Mammen AL, Danoff SK (2017) A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 56(6):999–1007
34.
Motegi SI et al (2019) Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 29(5):511–517PubMed
35.
Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T (2019) Clinical significance of serum chitotriosidase level in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease. J Rheumatol 46(8):935–942PubMed
36.
Chino H, Sekine A, Baba T, Kitamura H, Iwasawa T, Okudela K, Takemura T, Itoh H, Sato S, Suzuki Y, Ogura T (2019) Interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody: rapidly progressive perilobular opacity. Intern Med 58(18):2605–2613PubMedPubMedCentral
37.
Gonzalez-Moreno J et al (2018) Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review. Rheumatol Int 38(7):1293–1296PubMedPubMedCentral
38.
Li L, Wang Q, Wen X, Liu C, Wu C, Yang F, Zeng X, Li Y (2017) Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease. Oncotarget 8(44):76129–76140PubMedPubMedCentral
39.
Sugie K, Tonomura Y, Ueno S (2012) Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Intern Med 51(7):799–802PubMed
40.
Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Jobanputra R, Dankó K (2015) Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. Acta Reumatol Port 40(4):337–347PubMed
41.
Melguizo Madrid E et al (2019) Coexistence of anti-Jo1 and anti-signal recognition particle antibodies in a polymyositis patient. Reumatología Clínica (English Edition) 15(6):e111–e113
42.
Huang HL, Lin WC, Yeh CC, Sun YT (2020) Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy. J Clin Neurosci 74:32–35PubMed
43.
Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Gono T, Ukichi T, Kaieda S, Naniwa T, Kuwana M, JAMI investigators, Okano Y, Yamaguchi Y, Taniguchi Y, Kikuchi J, Kubo M, Watanabe M, Harada T, Kazuyori T, Kameda H, Kaburaki M, Matsuzawa Y, Yoshida S, Yoshioka Y, Hirai T, Wada Y, Ishii K, Fujiwara S, Saraya T, Morimoto K, Hara T, Suzuki H, Shibuya H, Muro Y, Aki R, Shibayama T, Ohshima S, Yasuda Y, Terada M, Kawahara Y (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford) 57:1212–1221
44.
Cen X et al (2013) A clinical analysis of risk factors for interstitial lung disease in patients with idiopathic inflammatory myopathy. Clin Dev Immunol 2013:648570PubMedPubMedCentral
Metadata
Title
The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease
Authors
Hung-Ling Huang
Wen-Chih Lin
Po-Yu Lin
Meng-Yu Weng
Yuan-Ting Sun
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 7/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04911-7

Other articles of this Issue 7/2021

Neurological Sciences 7/2021 Go to the issue

Retraction Note

Retraction Note: Musical practice and BDNF plasma levels as a potential marker of synaptic plasticity: an instrument of rehabilitative processes

COVID-19

Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage

Review Article

Constraint-induced movement therapy protocols using the number of repetitions of task practice: a systematic review of feasibility and effects

Original Article

Lipid profiles and their potential inflammatory effects in anti-N-methyl-D-aspartate receptor encephalitis

Original Article

Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19

COVID-19

Virtual visits for chronic neurologic disorders during COVID-19 pandemic